Status:
COMPLETED
Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease
Lead Sponsor:
Phytopharm
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.
Eligibility Criteria
Inclusion
- At least 50 years of age
- Diagnosis of possible or probable Alzheimer's disease
- Mini mental state examination score at least 16
- Good understanding of both written and verbal English
- A recent head scan that is consistent with the diagnosis of Alzheimer's disease
Exclusion
- Recent history or clinical evidence of significant neurological disease other than dementia due to Alzheimer's disease
- Known to have another condition that is associated with dementia
- Use of psychotropic medication within the previous 4 weeks (excluding cholinesterase inhibitors, selective serotonin reuptake inhibitors and venlafaxine)
- Hormone replacement therapy started or changed within the previous 6 months
- Received any investigational drugs within the previous 12 weeks
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00130429
Start Date
January 1 2004
End Date
September 1 2005
Last Update
August 21 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford Project to Investigate Memory and Ageing
Oxford, Oxfordshire, United Kingdom, OX3 7JX